83% of patients taking TYSABRI had no sustained physical disability progression for 12 weeks vs 71% with placebo (primary endpoint: percentage with sustained increase in disability was 17% vs 29%; p<0.001)1,2
View the complete AFFIRM study description.
Stephen Newman, MD, and patient Jennifer discuss evidence from the clinical trial as it relates to their own experiences with TYSABRI.
AFFIRM=NAtalizumab Safety and EFFIcacy in Relapsing-Remitting MS.
a190,800 patients as of August 2018.3